Evidence map›Paper›PMID 35411343›Full record

ArticleResearch square2022

Differential chromatin accessibility in peripheral blood mononuclear cells underlies COVID-19 disease severity prior to seroconversion.

Nicholas S Giroux, Shengli Ding, Micah T McClain, Thomas W Burke, Elizabeth Petzold, Hong A Chung, Grecia O Rivera, Ergang Wang, Rui Xi, Shree Bose and 14 more

Open access · greenAbstract readPreprint
In one paragraph

Article in Research square, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

24 authors at 2 institutions in 1 country.

Nicholas S GirouxDuke University.
Shengli DingDuke University.
Micah T McClainDuke University School of Medicine.
Thomas W BurkeDuke University School of Medicine.
Elizabeth PetzoldDuke University School of Medicine.
Hong A ChungDuke University.
Grecia O RiveraDuke University.
Ergang WangDuke University.
Rui XiDuke University.
Shree BoseDuke University.
Tomer RotsteinDuke University.
Bradly P NicholsonDurham Veterans Affairs Health Care System.
Tianyi ChenDuke University.
Ricardo HenaoDuke University School of Medicine.
Gregory D SempowskiDuke University.
Thomas N DennyDuke University.
Maria Iglesias De UsselDuke University School of Medicine.
Lisa L SatterwhiteDuke University.
Emily R KoDuke University School of Medicine.
Geoffrey S GinsburgDuke University School of Medicine.
Bryan D KraftDuke University School of Medicine.
Ephraim L TsalikDuke University School of Medicine.
Xiling ShenDuke University.
Christopher WoodsDuke University School of Medicine.
Duke University · USDurham VA Health Care System · US

Funding

NIAID VIROLOGY QUALITY ASSURANCE (VQA) COVID-1975N93019C00015 · NIAID · DUKE UNIVERSITY · PI DENNY, THOMAS · 2019 to 2025
$24.4M
Regional Biocontainment Laboratory (RBL)UC6AI058607 · NIAID · DUKE UNIVERSITY · PI WILLIAMS, R SANDERS · 2003 to 2005
$16.3M
Robust Control of the Stem Cell NicheR35GM122465 · NIGMS · TERASAKI INSTITUTE FOR BIOMEDICAL INNOVATION · PI Xiling Shen · 2017 to 2026
$5.6M
Role of S-nitrosothiols in Akt1 signaling and pneumonia resolutionK08HL130557 · NHLBI · DUKE UNIVERSITY · PI KRAFT, BRYAN D. · 2017 to 2021
$591k
NHLBI NIH HHS K08 HL130557NIAID NIH HHS 75N93019C00015NIAID NIH HHS UC6 AI058607NIGMS NIH HHS R35 GM122465
6 · The paper itself

Abstract

SARS-CoV-2 infection triggers profound and variable immune responses in human hosts. Chromatin remodeling has been observed in individuals severely ill or convalescing with COVID-19, but chromatin remodeling early in disease prior to anti-spike protein IgG seroconversion has not been defined. We performed the Assay for Transposase-Accessible Chromatin using sequencing (ATAC-seq) and RNA-seq on peripheral blood mononuclear cells (PBMCs) from outpatients with mild or moderate symptom severity at different stages of clinical illness. Early in the disease course prior to IgG seroconversion, modifications in chromatin accessibility associate with mild or moderate symptoms are already robust and include severity-associated changes in accessibility of genes in interleukin signaling, regulation of cell differentiation and cell morphology. Furthermore, single-cell analyses revealed evolution of the chromatin accessibility landscape and transcription factor motif accessibility for individual PBMC cell types over time. The most extensive remodeling occurred in CD14+ monocytes, where sub-populations with distinct chromatin accessibility profiles were observed prior to seroconversion. Mild symptom severity is marked by upregulation classical antiviral pathways including those regulating IRF1 and IRF7, whereas in moderate disease these classical antiviral signals diminish suggesting dysregulated and less effective responses. Together, these observations offer novel insight into the epigenome of early mild SARS-CoV-2 infection and suggest that detection of chromatin remodeling in early disease may offer promise for a new class of diagnostic tools for COVID-19.

Identifiers

PMID35411343
PMCPMC8996625
OpenAlexW4223568940

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.